Bleeding disorders:
Indications for: KOVALTRY
In patients with Hemophilia A: to treat and control bleeding episodes, for perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
Adults and Children:
Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Individualize. Infuse over 1–15mins. Bleeding: Minor: obtain 20–40% FVIII increase; may repeat every 12–24hrs for ≥1 day until resolved or healing is achieved; Moderate: obtain 30–60% FVIII increase; may repeat every 12–24hrs for 3–4 days until pain and acute disability resolved; Major: obtain 60–100% FVIII increase; may repeat every 8–24hrs until resolved. Perioperative: Minor (pre- and post-op): obtain 30–60% FVIII increase; may repeat every 24hrs for ≥1 day until healed; Major (pre- and post-op): obtain 80–100% FVIII increase; may repeat every 8–24hrs until adequately healed, then continue for ≥7 days to maintain Factor VIII activity of 30–60%. Routine prophylaxis: >12yrs: 20–40 IU/kg 2–3 times weekly; ≤12yrs: 25–50 IU/kg 2–3 times weekly or every other day according to requirements.
KOVALTRY Contraindications:
Mouse or hamster protein sensitivity.
KOVALTRY Warnings/Precautions:
Confirm Factor VIII deficiency prior to treatment. Monitor for development of Factor VIII inhibitors. Cardiovascular disease or risk factors. Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.
KOVALTRY Classification:
Clotting factor.
Adverse Reactions:
Headache, pyrexia, pruritus, inj site reactions, rash; antibody formation, catheter-related infections.
Generic Drug Availability:
NO
How Supplied:
Kit—1 (vial w. diluent and adapter)
